Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer
Abstract SET domain bifurcated histone lysine methyltransferase 1 (SETDB1/ESET), a pivotal H3K9 methyltransferase, has been extensively studied since its discovery over two decades ago. SETDB1 plays critical roles in immune regulation, including B cell maturation, T‐cell activity modulation, and end...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Kaohsiung Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/kjm2.12933 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850035376008200192 |
|---|---|
| author | Bo‐Syong Pan Cheng‐Yu Lin Gilbert Aaron Lee Hui‐Kuan Lin |
| author_facet | Bo‐Syong Pan Cheng‐Yu Lin Gilbert Aaron Lee Hui‐Kuan Lin |
| author_sort | Bo‐Syong Pan |
| collection | DOAJ |
| description | Abstract SET domain bifurcated histone lysine methyltransferase 1 (SETDB1/ESET), a pivotal H3K9 methyltransferase, has been extensively studied since its discovery over two decades ago. SETDB1 plays critical roles in immune regulation, including B cell maturation, T‐cell activity modulation, and endogenous retrovirus (ERV) silencing. While essential for normal immune cell function, SETDB1 overexpression in cancer cells disrupts immune responses by suppressing tumor immunogenicity and facilitating immune evasion. This is achieved through the repression of anti‐tumor immune cell production, ERV silencing, and interference with the type I interferon pathway leading to inhibiting immune checkpoint blockade (ICB) efficacy. Beyond its immunological implications, SETDB1 overexpression fosters tumor growth and metastasis via transcriptional silencing of tumor suppressor genes through histone regulation and activating oncogenic signaling by non‐histone regulation. These multifaceted roles make SETDB1 an attractive epigenetic target for novel cancer therapies. This review explores SETDB1's dual function in immune regulation and tumor progression, emphasizing its potential in the development of innovative cancer treatments targeting epigenetic dysregulation and oncogenic signaling. |
| format | Article |
| id | doaj-art-47a5cdf1b9cf401e9eb6eea7ad950d77 |
| institution | DOAJ |
| issn | 1607-551X 2410-8650 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Kaohsiung Journal of Medical Sciences |
| spelling | doaj-art-47a5cdf1b9cf401e9eb6eea7ad950d772025-08-20T02:57:30ZengWileyKaohsiung Journal of Medical Sciences1607-551X2410-86502025-03-01413n/an/a10.1002/kjm2.12933Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancerBo‐Syong Pan0Cheng‐Yu Lin1Gilbert Aaron Lee2Hui‐Kuan Lin3Department of Pathology Duke University Medical Center Durham North Carolina USADepartment of Pathology Duke University Medical Center Durham North Carolina USADepartment of Pathology Duke University Medical Center Durham North Carolina USADepartment of Pathology Duke University Medical Center Durham North Carolina USAAbstract SET domain bifurcated histone lysine methyltransferase 1 (SETDB1/ESET), a pivotal H3K9 methyltransferase, has been extensively studied since its discovery over two decades ago. SETDB1 plays critical roles in immune regulation, including B cell maturation, T‐cell activity modulation, and endogenous retrovirus (ERV) silencing. While essential for normal immune cell function, SETDB1 overexpression in cancer cells disrupts immune responses by suppressing tumor immunogenicity and facilitating immune evasion. This is achieved through the repression of anti‐tumor immune cell production, ERV silencing, and interference with the type I interferon pathway leading to inhibiting immune checkpoint blockade (ICB) efficacy. Beyond its immunological implications, SETDB1 overexpression fosters tumor growth and metastasis via transcriptional silencing of tumor suppressor genes through histone regulation and activating oncogenic signaling by non‐histone regulation. These multifaceted roles make SETDB1 an attractive epigenetic target for novel cancer therapies. This review explores SETDB1's dual function in immune regulation and tumor progression, emphasizing its potential in the development of innovative cancer treatments targeting epigenetic dysregulation and oncogenic signaling.https://doi.org/10.1002/kjm2.12933cancerendogenous retrovirus silencingimmune checkpoint blockagemethyltransferaseSETDB1 |
| spellingShingle | Bo‐Syong Pan Cheng‐Yu Lin Gilbert Aaron Lee Hui‐Kuan Lin Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer Kaohsiung Journal of Medical Sciences cancer endogenous retrovirus silencing immune checkpoint blockage methyltransferase SETDB1 |
| title | Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer |
| title_full | Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer |
| title_fullStr | Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer |
| title_full_unstemmed | Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer |
| title_short | Targeting SETDB1 in cancer and immune regulation: Potential therapeutic strategies in cancer |
| title_sort | targeting setdb1 in cancer and immune regulation potential therapeutic strategies in cancer |
| topic | cancer endogenous retrovirus silencing immune checkpoint blockage methyltransferase SETDB1 |
| url | https://doi.org/10.1002/kjm2.12933 |
| work_keys_str_mv | AT bosyongpan targetingsetdb1incancerandimmuneregulationpotentialtherapeuticstrategiesincancer AT chengyulin targetingsetdb1incancerandimmuneregulationpotentialtherapeuticstrategiesincancer AT gilbertaaronlee targetingsetdb1incancerandimmuneregulationpotentialtherapeuticstrategiesincancer AT huikuanlin targetingsetdb1incancerandimmuneregulationpotentialtherapeuticstrategiesincancer |